Apogee Therapeutics (APGE) Current Assets (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Current Assets data on file, last reported at $1.1 billion in Q1 2026.

• On a quarterly basis, Current Assets rose 105.89% year-over-year to $1.1 billion in Q1 2026; TTM through Mar 2026 was $1.1 billion, a 105.89% increase from a year earlier, with the FY2025 full-year figure at $741.4 million, up 39.95% from the prior year.
• Current Assets for Q1 2026 stood at $1.1 billion, up from $741.4 million in the prior quarter.
• Over the last five years, Current Assets for APGE reached as high as $1.1 billion in Q1 2026 and fell as low as $130.7 million in Q2 2023.
• Historically, Current Assets has averaged $543.6 million across 5 years, with a median of $529.7 million in 2024.
• Across the five-year window, Current Assets soared 421.82% in 2024 and plunged 36.45% in 2025, its largest moves.
• Year by year, Current Assets stood at $152.1 million in 2022, then soared by 162.02% to $398.4 million in 2023, then surged by 32.96% to $529.7 million in 2024, then surged by 39.95% to $741.4 million in 2025, then soared by 44.84% to $1.1 billion in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $1.1 billion in Q1 2026, $741.4 million in Q4 2025, and $540.1 million in Q3 2025.